D
Dan Aderka
Researcher at Sheba Medical Center
Publications - 22
Citations - 4187
Dan Aderka is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 10, co-authored 22 publications receiving 3214 citations.
Papers
More filters
Journal ArticleDOI
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem,Andrés Cervantes,René Adam,Alberto Sobrero,J.H.J.M. van Krieken,Dan Aderka,E. Aranda Aguilar,Alberto Bardelli,Al B. Benson,György Bodoky,Fortunato Ciardiello,André D'Hoore,Eduardo Díaz-Rubio,J.-Y. Douillard,Michel Ducreux,Alfredo Falcone,Axel Grothey,Thomas Gruenberger,Karin Haustermans,Volker Heinemann,Paulo M. Hoff,C.-H. Köhne,R. Labianca,Pierre Laurent-Puig,Brigette B.Y. Ma,Tim Maughan,Kei Muro,Nicola Normanno,Pia Österlund,Pia Österlund,Wim J.G. Oyen,Demetris Papamichael,George Pentheroudakis,Per Pfeiffer,Timothy J. Price,C.J.A. Punt,Jens Ricke,Arnaud Roth,R. Salazar,Werner Scheithauer,H.-J. Schmoll,Josep Tabernero,Julien Taieb,Sabine Tejpar,Harpreet Wasan,Takayuki Yoshino,Aziz Zaanan,Dirk Arnold +47 more
TL;DR: These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.
Journal ArticleDOI
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
H.-J. Schmoll,E. Van Cutsem,Alexander Stein,Vincenzo Valentini,Bengt Glimelius,Bengt Glimelius,Karin Haustermans,Bernard Nordlinger,C.J.H. van de Velde,Judith Balmaña,Jaroslaw Regula,Iris D. Nagtegaal,Regina G. H. Beets-Tan,D Arnold,Fortunato Ciardiello,Paulo M. Hoff,David J. Kerr,C.-H. Köhne,Roberto Labianca,Timothy J. Price,Werner Scheithauer,Alberto Sobrero,Josep Tabernero,Dan Aderka,S Barroso,György Bodoky,J.-Y. Douillard,H El Ghazaly,Jorge Gallardo,August Garin,Rob Glynne-Jones,Karin Jordan,A Meshcheryakov,D Papamichail,Per Pfeiffer,Ioannis Souglakos,Serdar Turhal,Andrés Cervantes +37 more
TL;DR: This ESMO guideline is recommended to be used as the basis for treatment and management decisions, delivering a clear proposal for diagnostic and treatment measures in each stage of rectal and colon cancer and the individual clinical situations.
Journal ArticleDOI
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Sebastian Stintzing,Pratyaksha Wirapati,H. J. Lenz,Daniel Neureiter,L. Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Florian Kaiser,S-E. Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Markus Moehler,Werner Scheithauer,Swantje Held,Dominik Paul Modest,Andreas Jung,T. Kirchner,Dan Aderka,Sabine Tejpar,Volker Heinemann +22 more
TL;DR: CMS classification provides deeper insights into the biology to CRC, but at present time has no direct impact on clinical decision-making.
Journal ArticleDOI
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors.
Jesus Garcia-Foncillas,Yu Sunakawa,Dan Aderka,Zev A. Wainberg,Philippe Ronga,Pauline Witzler,Sebastian Stintzing +6 more
TL;DR: It is concluded that cetuximab and panitumumab are distinct therapeutic agents that should be considered individually during treatment planning and may provide a rationale for this antibody as a combination partner with investigational chemotherapy plus immunotherapy regimens for colorectal cancer.
Journal ArticleDOI
PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
TL;DR: It is suggested that 18F-FDG PET may be instrumental for predicting the pathologic response to Bevacizumab based therapy.